{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:29:12Z","timestamp":1760189352013},"reference-count":59,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Although there have been recent advances with targeted therapies in chronic lymphocytic leukemia (CLL), chemoimmunotherapy remains the treatment of choice; however, this approach is not curative. A key feature of CLL is that it induces a state of immunosuppression, causing increased susceptibility to infections and failure of an antitumor immune response, often worsened by the immunosuppressive effect of treatment. Because of its improved specificity, immunotherapy potentially offers a way out of this dilemma. Allogeneic stem cell transplantation remains the only curative option, but is hampered by the toxicity of GVHD. After many years of promise but little reward, many other immunotherapeutic approaches are now in transition to the clinical setting. Clinical trials including CLL vaccines, CXCR4 antagonists, and adoptive cellular immunotherapies such as chimeric antigen receptor\u2013modified T cells, CD40 ligand gene therapy, and the immunomodulatory drug lenalidomide are ongoing. Results to date suggest that immunotherapeutic approaches for the treatment of CLL might finally be fulfilling their promise.<\/jats:p>","DOI":"10.1182\/asheducation-2013.1.151","type":"journal-article","created":{"date-parts":[[2013,12,6]],"date-time":"2013-12-06T15:51:13Z","timestamp":1386345073000},"page":"151-157","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":11,"title":["Immunotherapeutic strategies including transplantation: eradication of disease"],"prefix":"10.1182","volume":"2013","author":[{"given":"John G.","family":"Gribben","sequence":"first","affiliation":[{"name":"Barts Cancer Institute, Queen Mary University of London, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John C.","family":"Riches","sequence":"additional","affiliation":[{"name":"Barts Cancer Institute, Queen Mary University of London, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"2","key":"2019111703544174700_B1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1182\/blood-2009-08-207126","article-title":"How I treat CLL up front","volume":"115","author":"Gribben","year":"2010","journal-title":"Blood"},{"issue":"9747","key":"2019111703544174700_B2","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"issue":"9","key":"2019111703544174700_B3","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1200\/JCO.2011.36.9348","article-title":"Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial","volume":"30","author":"Bottcher","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111703544174700_B4","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.hoc.2013.01.005","article-title":"The role of minimal residual disease measurements in the therapy for CLL: is it ready for prime time?","volume":"27","author":"Bottcher","year":"2013","journal-title":"Hematol Oncol Clin North Am"},{"issue":"18","key":"2019111703544174700_B5","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.1182\/blood-2011-11-312421","article-title":"Risk categories and refractory CLL in the era of chemoimmunotherapy","volume":"119","author":"Zenz","year":"2012","journal-title":"Blood"},{"issue":"12","key":"2019111703544174700_B6","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1182\/blood-2008-03-077974","article-title":"Graft-versus-leukemia effects of transplantation and donor lymphocytes","volume":"112","author":"Kolb","year":"2008","journal-title":"Blood"},{"key":"2019111703544174700_B7","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.bbmt.2008.10.022","article-title":"Stem cell transplantation in chronic lymphocytic leukemia","volume":"15","author":"Gribben","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"16","key":"2019111703544174700_B8","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1182\/blood-2012-11-469627","article-title":"TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial","volume":"121","author":"Dreger","year":"2013","journal-title":"Blood"},{"issue":"20","key":"2019111703544174700_B9","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1002\/cncr.26091","article-title":"Nonmyeloablative allogeneic stem cell transplantation in relapsed\/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome","volume":"117","author":"Khouri","year":"2011","journal-title":"Cancer"},{"issue":"30","key":"2019111703544174700_B10","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1200\/JCO.2007.15.4757","article-title":"Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning","volume":"26","author":"Sorror","year":"2008","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111703544174700_B11","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/leu.2012.228","article-title":"Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome","volume":"27","author":"Brown","year":"2013","journal-title":"Leukemia"},{"issue":"1","key":"2019111703544174700_B12","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/sj.leu.2404441","article-title":"Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus","volume":"21","author":"Dreger","year":"2007","journal-title":"Leukemia"},{"issue":"31","key":"2019111703544174700_B13","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.1200\/JCO.2008.16.2982","article-title":"Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis","volume":"26","author":"Schetelig","year":"2008","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111703544174700_B14","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1182\/blood-2010-09-308775","article-title":"Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation","volume":"117","author":"Michallet","year":"2011","journal-title":"Blood"},{"issue":"7","key":"2019111703544174700_B15","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1182\/blood-2003-05-1549","article-title":"The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia:a risk-matched analysis based on the VH gene mutational status","volume":"103","author":"Dreger","year":"2004","journal-title":"Blood"},{"issue":"21","key":"2019111703544174700_B16","doi-asserted-by":"crossref","first-page":"4851","DOI":"10.1182\/blood-2011-09-378505","article-title":"Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trial","volume":"119","author":"Dreger","year":"2012","journal-title":"Blood"},{"issue":"16","key":"2019111703544174700_B17","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1182\/blood-2009-12-257147","article-title":"The number of cytomegalovirus-specific CD4+ T cells is markedly expanded in patients with B-cell chronic lymphocytic leukemia and determines the total CD4+ T-cell repertoire","volume":"116","author":"Pourgheysari","year":"2010","journal-title":"Blood"},{"issue":"9","key":"2019111703544174700_B18","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1182\/blood-2012-09-457531","article-title":"T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production","volume":"121","author":"Riches","year":"2013","journal-title":"Blood"},{"issue":"7","key":"2019111703544174700_B19","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1172\/JCI24176","article-title":"Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells","volume":"115","author":"Gorgun","year":"2005","journal-title":"J Clin Invest"},{"issue":"7","key":"2019111703544174700_B20","first-page":"2427","article-title":"Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug","volume":"118","author":"Ramsay","year":"2008","journal-title":"J Clin Invest"},{"issue":"7","key":"2019111703544174700_B21","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1182\/blood-2012-02-411678","article-title":"Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer","volume":"120","author":"Ramsay","year":"2012","journal-title":"Blood"},{"issue":"14","key":"2019111703544174700_B22","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1182\/blood-2012-08-448332","article-title":"Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide","volume":"121","author":"Ramsay","year":"2013","journal-title":"Blood"},{"issue":"6","key":"2019111703544174700_B23","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1182\/blood-2005-02-0642","article-title":"Reduced frequencies and suppressive function of CD4+ CD25high regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine","volume":"106","author":"Beyer","year":"2005","journal-title":"Blood"},{"issue":"3","key":"2019111703544174700_B24","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.leukres.2008.08.021","article-title":"Disruption of T cell suppression in chronic lymphocytic leukemia by CD200 blockade","volume":"33","author":"Pallasch","year":"2009","journal-title":"Leuk Res"},{"issue":"20","key":"2019111703544174700_B25","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1182\/blood-2010-12-324210","article-title":"A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease","volume":"117","author":"Bagnara","year":"2011","journal-title":"Blood"},{"issue":"13","key":"2019111703544174700_B26","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1182\/blood-2008-07-170415","article-title":"High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation","volume":"113","author":"Burger","year":"2009","journal-title":"Blood"},{"issue":"5","key":"2019111703544174700_B27","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1182\/blood-2010-09-307249","article-title":"CCL3(MIP-1alpha) plasma levels and the risk for disease progression in chronic lymphocytic leukemia","volume":"117","author":"Sivina","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2019111703544174700_B28","doi-asserted-by":"crossref","first-page":"953","DOI":"10.3324\/haematol.2012.077537","article-title":"The PD-1\/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia","volume":"98","author":"Brusa","year":"2013","journal-title":"Haematologica"},{"issue":"7077","key":"2019111703544174700_B29","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nature04444","article-title":"Restoring function in exhausted CD8 T cells during chronic viral infection","volume":"439","author":"Barber","year":"2006","journal-title":"Nature"},{"issue":"7109","key":"2019111703544174700_B30","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature05115","article-title":"PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression","volume":"443","author":"Day","year":"2006","journal-title":"Nature"},{"issue":"4","key":"2019111703544174700_B31","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"2019111703544174700_B32","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"26","key":"2019111703544174700_B33","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"issue":"26","key":"2019111703544174700_B34","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMe1205943","article-title":"Tumor immunotherapy directed at PD-1","volume":"366","author":"Ribas","year":"2012","journal-title":"N Engl J Med"},{"issue":"26","key":"2019111703544174700_B35","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111703544174700_B36","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1158\/1078-0432.CCR-07-4079","article-title":"Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies","volume":"14","author":"Berger","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"18","key":"2019111703544174700_B37","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1182\/blood-2012-08-448977","article-title":"Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation","volume":"121","author":"Blyth","year":"2013","journal-title":"Blood"},{"issue":"22","key":"2019111703544174700_B38","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2010-05-283309","article-title":"The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor","volume":"116","author":"Hudecek","year":"2010","journal-title":"Blood"},{"issue":"8","key":"2019111703544174700_B39","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1073\/pnas.0712148105","article-title":"Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a","volume":"105","author":"Fukuda","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5796","key":"2019111703544174700_B40","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1126\/science.1129003","article-title":"Cancer regression in patients after transfer of genetically engineered lymphocytes","volume":"314","author":"Morgan","year":"2006","journal-title":"Science"},{"issue":"10","key":"2019111703544174700_B41","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/nri2635","article-title":"Engineering lymphocyte subsets: tools, trials and tribulations","volume":"9","author":"June","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"2019111703544174700_B42","doi-asserted-by":"crossref","first-page":"956304","DOI":"10.1155\/2010\/956304","article-title":"Chimeric antigen receptor-engineered T cells for immunotherapy of cancer","volume":"2010","author":"Cartellieri","year":"2010","journal-title":"J Biomed Biotechnol"},{"issue":"18","key":"2019111703544174700_B43","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"issue":"8","key":"2019111703544174700_B44","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"issue":"95","key":"2019111703544174700_B45","doi-asserted-by":"crossref","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med"},{"issue":"12","key":"2019111703544174700_B46","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"},{"issue":"5","key":"2019111703544174700_B47","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1172\/JCI46110","article-title":"CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients","volume":"121","author":"Savoldo","year":"2011","journal-title":"J Clin Invest"},{"issue":"16","key":"2019111703544174700_B48","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111703544174700_B49","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/mt.2010.31","article-title":"Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells:case report of an unforeseen adverse event in a phase I clinical trial","volume":"18","author":"Brentjens","year":"2010","journal-title":"Mol Ther"},{"issue":"2","key":"2019111703544174700_B50","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/CJI.0b013e3182811ce9","article-title":"Sleeping beauty system to redirect T-cell specificity for human applications","volume":"36","author":"Maiti","year":"2013","journal-title":"J Immunother"},{"issue":"12","key":"2019111703544174700_B51","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1158\/1078-0432.CCR-13-0330","article-title":"Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T-cells","volume":"19","author":"Hudecek","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2019111703544174700_B52","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1182\/blood.V96.9.2917","article-title":"CD40-ligand(CD154) gene therapy for chronic lymphocytic leukemia","volume":"96","author":"Wierda","year":"2000","journal-title":"Blood"},{"issue":"11","key":"2019111703544174700_B53","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1038\/leu.2010.191","article-title":"A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154","volume":"24","author":"Wierda","year":"2010","journal-title":"Leukemia"},{"issue":"12","key":"2019111703544174700_B54","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1158\/0008-5472.CAN-11-3368","article-title":"Gene immunotherapy of chronic lymphocytic leukemia: a phase I study of intranodally injected adenovirus expressing a chimeric CD154 molecule","volume":"72","author":"Castro","year":"2012","journal-title":"Cancer Res"},{"issue":"9","key":"2019111703544174700_B55","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1200\/JCO.2010.29.8133","article-title":"Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia","volume":"29","author":"Chen","year":"2011","journal-title":"J Clin Oncol"},{"issue":"13","key":"2019111703544174700_B56","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2011-03-339077","article-title":"Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia","volume":"118","author":"Badoux","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2019111703544174700_B57","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1200\/JCO.2012.42.8623","article-title":"Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia","volume":"31","author":"Badoux","year":"2013","journal-title":"J Clin Oncol"},{"issue":"20","key":"2019111703544174700_B58","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1182\/blood-2012-12-470005","article-title":"Long-term repair of T-cell synapse activity in a phase 2 trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL)","volume":"121","author":"Shanafelt","year":"2013","journal-title":"Blood"},{"issue":"9","key":"2019111703544174700_B59","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.3324\/haematol.2009.009274","article-title":"Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drug","volume":"94","author":"Ramsay","year":"2009","journal-title":"Haematologica"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2013\/1\/151\/1251027\/bep00113000151.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2013\/1\/151\/1251027\/bep00113000151.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T08:55:01Z","timestamp":1573980901000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2013\/1\/151\/20879\/Immunotherapeutic-strategies-including"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,6]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2013.1.151","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,6]]}}}